Activator protein of human acid maltase and uses thereof
OwnerFrank T. Martiniukinventor
Life of this patent
Estimating the term…
Loading patent…
OwnerFrank T. Martiniukinventor
Estimating the term…
The present invention relates to compositions and methods for treating glycogen storage disease, such as GSD II. A human activator enzyme, termed ASA, of acid a a-glycosidase, (GAA) or acid maltase, a lysosomal enzyme, is specifically defined and characterized. The AGA has been found to increase the activity of human acid α glycosidase activity to at least 10-fold, relative to the activity of GAA in the absence of the activator protein. The invention thus also provides for a method of increasing the activity of GAA, particularly through the action of AGA. The AGA has an approximate molecular weight of 25-30 kD, and is found to be heat stable. In addition, the AGA is found to have an extended shelf life without significant loss of ability to activate GAA. The invention further reports other enzymes such as β-Fucosidase, β-Lactase, and β-Galactosidase, that provide enhancement of enzymatic activity nine-fold, six-fold, and five-fold, for breakdown of their respective substrate protein. These enzymes are non-lysosomal enzymes. These are anticipated to be useful in treatment of disease related to reduced enzymatic activity levels in an animal.
A composition comprising a human activation protein of human acid maltase (AGA), said activation protein being capable of enhancing human placental acid alpha glucosidase (GAA) activity at least 10-fold over GAA activity in the absence of human acid maltase (AGA).
A composition comprising β-Fucosidase, said β-Fucosidase being capable of enhancing biological activity up to nine-fold.
A composition comprising β-Lactase, said β-Lactase being capable of enhancing biological activity of up to six-fold.
A composition comprising β-Galactosidase, said β-Galactosidase being capable of enhancing biological activity up to five-fold.
Dependencies are inferred from the claim text.